NasdaqCM - Nasdaq Real Time Price USD

BioRestorative Therapies, Inc. (BRTX)

1.5600 -0.0400 (-2.50%)

As of 11:44:53 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

BioRestorative Therapies Announces Reverse Stock Split

GlobeNewswire 2mo ago

BRTX
-2.50%
^IXIC
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

GlobeNewswire 4mo ago

BRTX
-2.50%
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

GlobeNewswire 4mo ago

BRTX
-2.50%
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

CNW Group 5mo ago

BRTX
-2.50%
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

PR Newswire 5mo ago

BRTX
-2.50%
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

GlobeNewswire 5mo ago

BRTX
-2.50%
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

GlobeNewswire 5mo ago

BRTX
-2.50%
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

GlobeNewswire 6mo ago

BRTX
-2.50%
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

GlobeNewswire 6mo ago

BRTX
-2.50%
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

GlobeNewswire 6mo ago

BRTX
-2.50%
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

GlobeNewswire 7mo ago

BRTX
-2.50%
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

GlobeNewswire 8mo ago

BRTX
-2.50%

Performance Overview

Return	BRTX	S&P 500 (^GSPC)
YTD	+32.77%	+9.49%
1-Year	+13.04%	+9.70%
3-Year	-17.46%	+69.76%

U.S. markets close in 3h 17m

BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies Announces Reverse Stock Split

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy